The BioInsights Podcast
Can AAV continue to deliver the promise of gene therapy?
Rewind Speed Chapters
Chapters
0:50
Does AAV still reign supreme for advanced therapies?
5:50
What has AAV evolved over the past 5 years and how do you see the future?
11:54
As use of AAV continues to grow, what challenges stand in its way?
14:23
What promising innovations in AAV production do you see emerging over the next 5 years?
17:52
How can we streamline AAV manufacturing for common disease indications?
Forward
Info
The BioInsights Podcast
Can AAV continue to deliver the promise of gene therapy?
Sep 13, 2023 Season 2 Episode 13
BioInsights

In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senior Strategy Consultant at Merck Life Sciences. 

Share